Table 2.
Immune Activation, Ki67 Expression, and TREC Content in Lymphocyte Subsets in Control and HIV-Infected Subjects
| Controls | HIV-2-LV | HIV-2-HV | HIV-1 | P Valuea | |
|---|---|---|---|---|---|
| HLA-DR/CD38 coexpression (%) | |||||
| CD4+CD45RA+ | 2.83 (1.45–4.69) | 3.98 (3.39–4.47) | 9.94 (6.40–16.0) | 6.15 (3.92–6.95) | .012 |
| CD8+CD45RA+ | 2.80 (2.05–3.48) | 5.47 (4.15–6.05) | 14.89 (6.97–21.1) | 8.41 (6.13–9.69) | <.001 |
| CD4+CD45RA− | 2.33 (1.47–3.48) | 3.77 (3.04–6.05) | 6.14 (3.59–21.1) | 5.12 (4.46–9.69) | .059 |
| CD8+CD45RA− | 5.91 (3.96–10.1) | 11.69 (7.88–13.3) | 24.24 (14.51–31.8) | 17.67 (11.3–18.9) | <.001 |
| Ki67 expression (%) | |||||
| CD4+CD45RA+ | 1.12 (0.56–2.01) | 1.13 (0.95–1.69) | 3.30 (1.76–9.2) | 1.60 (1.25–2.11) | .082 |
| CD8+CD45RA+ | 3.22 (1.88–4.06) | 1.93 (1.78–2.34) | 4.51 (3.30–11.0) | 2.69 (2.22–3.29) | .052 |
| CD4+CD45RA− | 4.88 (3.07–4.06) | 4.84 (4.14–2.34) | 9.14 (7.09–11.0) | 6.56 (5.01–3.29) | .055 |
| CD8+CD45RA− | 5.61 (4.19–6.90) | 4.99 (3.53–6.90) | 11.06 (6.93–16.1) | 8.14 (7.05–11.1) | .035 |
| sjTREC (log copies/105 cells) | |||||
| CD4+CD45R0− | 4.43 (4.17–4.51) | 4.13 (3.63–4.17) | 3.58 (3.38–3.65) | 4.10 (3.33–4.41) | .004 |
| CD8+CD45R0− | 4.23 (4.06–4.40) | 4.03 (3.90–4.21) | 3.49 (3.33–4.02) | 4.00 (3.94–4.11) | .189 |
Values represent median (IQR).
Abbreviations: ANOVA, analysis of variance; HIV, human immunodeficiency virus; HIV-2-HV, HIV-2 infected with high viral load (>1000 copies/mL); HIV-2-LV, HIV-2 infected with low viral load (<100 copies/mL); IQR, interquartile range; TREC, T-cell receptor excision circle.
a P value represents comparison of groups by ANOVA.